pharmaphorum| News & views on pharma and biotech’s evolving future

R&D

Sponsored

Solution Spotlight: Inventus Control (Mobile Device Manageme...

Through Inventus Control, Inventus delivers a dedicated Mobile Device Management (MDM) platform for the life sciences sector.

News

Image of a pair of lungs on an orange-beige background

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

Market Access

Direct-to-patient access: Five questions pharma must answer

News

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.

News

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.

Featured Content

R&D

Sponsored

Solution Spotlight: Inventus Control (Mobile Device Manageme...

Through Inventus Control, Inventus delivers a dedicated Mobile Device Management (MDM) platform for the life sciences sector.

Spotlight on

ASCO 2026

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Oncology

pharmaphorum podcast Episode 264, ITM's Dr Andrew Cavey

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.

News

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.

News

CARSgen bags world-first approval for solid tumour CAR-T

CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.

Views & Analysis

R&D

Sponsored

Solution Spotlight: Inventus Control (Mobile Device Manageme...

Through Inventus Control, Inventus delivers a dedicated Mobile Device Management (MDM) platform for the life sciences sector.

Patients

Patient engagement drives clinical and commercial success

Engagement solutions can tap into long-lasting patient motivations that sustain behaviour.

Oncology

ASCO 2026 reshapes oncology trial design

The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo

Oncology

Liquid biopsy and the future of tumour-agnostic treatments

Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

Oncology

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother

Patients